Muscular Atrophy clinical trials at UC Irvine

4 research studies open to eligible people

Showing trials for

  • Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

    open to eligible males ages 18 years and up

    This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of study drug AJ201 in subjects with Spinal and Bulbar Muscular Atrophy (SBMA).

    Orange, California and other locations

  • Risdiplam in Participants With Spinal Muscular Atrophy (SMA)

    open to all eligible people

    A multi-center, longitudinal, prospective, non-comparative study to investigate the long-term safety and effectiveness of risdiplam, prescribed based on clinician judgment as per the Evrysdi® U.S. Package Insert (USPI) in adult and pediatric participants with spinal muscular atrophy (SMA). In this study, participants will be followed for up to 5 years from enrollment or until withdrawal of consent, loss to follow-up, or death. Participants who discontinue risdiplam may still remain in the study, if they agree to continue participating in the follow-up assessments.

    Orange, California and other locations

  • IMMUNA(IMM01-STEM) in Patients With Muscle Atrophy Related to Knee Osteoarthritis.

    open to eligible people ages 50-75

    An open-label dose escalation study to assess the safety and tolerability of IMMUNA(IMM01-STEM) in participants with muscle atrophy related to knee osteoarthritis

    Orange, California

  • Clinical Procedures to Support Research in ALS

    open to eligible people ages 18 years and up

    The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.

    Irvine, California and other locations

Our lead scientists for Muscular Atrophy research studies include .

Last updated: